Table 2

Expected probabilities of ACR response by bDMARD exposure subgroup for key comparators

Intervention*Probability of response, median (95% credible interval)
All patientsbDMARD-naïvebDMARD-exposed
ACR 20ACR 50ACR 70ACR 20ACR 50ACR 70ACR 20ACR 50ACR 70
Brodalumab 210 mg48.6%
(37.6, 59.7)
24.6%
(16.7, 34.3)
9.8%
(16.7, 34.3)
53.1%
(40.4, 65.3)
28.5%
(18.7, 40)
13%
(18.7, 40)
32.3%
(15.9, 53.1)
14.7%
(5.6, 30.6)
5.4%
(5.6, 30.6)
Ixekizumab 80 mg every two weeks56%
(44.5, 66.6)
30.9%
(21.5, 41.3)
13.4%
(21.5, 41.3)
60.2%
(45.1, 74.2)
34.9%
(22.1, 50.1)
17.3%
(22.1, 50.1)
47.2%
(28.1, 67)
25.5%
(12.1, 44.1)
11.2%
(12.1, 44.1)
Ixekizumab 80 mg every four weeks55.1%
(44.5, 64.8)
30%
(21.5, 39.3)
12.9%
(21.5, 39.3)
55.5%
(43.1, 67.7)
30.6%
(20.6, 42.5)
14.4%
(20.6, 42.5)
49.4%
(29.9, 69)
27.3%
(13.2, 46.4)
12.2%
(13.2, 46.4)
Secukinumab 150 mg51.5%
(42.7, 60.4)
27%
(20.2, 35)
11.1%
(20.2, 35)
54.2%
(45.4, 63.3) †
29.4%
(22.2, 38) †
13.6%
(22.2, 38) †
40.7%
(23.7, 59.7) †
20.5%
(9.6, 36.6) †
8.3%
(9.6, 36.6) †
Secukinumab 300 mg56.3%
(47.4, 64.8)
31.2%
(23.7, 39.4)
13.6%
(23.7, 39.4)
57.2%
(48.2, 66.3)†
32.1%
(24.4, 41.1)†
15.4%
(24.4, 41.1)†
51%
(32.2, 69.4) †
28.6%
(14.7, 46.9)†
13.1%
(14.7, 46.9)†
Guselkumab 100 mg every eight weeks51.6%
(40.5, 61)
27.1%
(18.6, 35.5)
11.1%
(18.6, 35.5)
52.6%
(41, 63.4)†
28.1%
(19.1, 38.1)†
12.8%
(19.1, 38.1)†
63%
(36.2, 84.8)‡
39.8%
(17.3, 67)‡
20.7%
(17.3, 67)‡
Tildrakizumab 100 mg every twelve weeks48.9%
(32.9, 64.3)
24.9%
(13.7, 38.8)
9.9%
(13.7, 38.8)
Ustekinumab 45 mg34.2%
(24.6, 45.9)
14.5%
(9.1, 22.5)
4.8%
(9.1, 22.5)
41.8%
(29.7, 55.1)
19.6%
(11.9, 30.2)
7.9%
(11.9, 30.2)
32.9%
(13.6, 59)
15.1%
(4.6, 36)
5.6%
(4.6, 36)
Ustekinumab 90 mg41.6%
(32, 52.7)
19.4%
(13.2, 28)
7.1%
(13.2, 28)
46%
(33.5, 59)
22.8%
(14.1, 33.8)
9.6%
(14.1, 33.8)
31.9%
(13, 57.9)
14.5%
(4.3, 34.9)
5.3%
(4.3, 34.9)
Adalimumab 40 mg every two weeks55.8%
(46.5, 63.6)
30.7%
(23, 38.1)
13.3%
(23, 38.1)
55.5%
(46.3, 64.8)
30.6%
(22.9, 39.4)
14.4%
(22.9, 39.4)
Certolizumab 200 mg every two weeks61.3%
(47.1, 73.8)
35.8%
(23.5, 49.4)
16.6%
(23.5, 49.4)
55.8%
(41, 70.3)
30.9%
(19.1, 45.4)
14.6%
(19.1, 45.4)
65.3%
(36.4, 88.1)
42.2%
(17.5, 72.3)
22.5%
(17.5, 72.3)
Certolizumab 400 mg every four weeks52.2%
(37.9, 65.7)
27.6%
(16.9, 40.3)
11.5%
(16.9, 40.3)
Etanercept 50 mg once weekly61.8%
(47.2, 75.6)
36.3%
(23.6, 51.7)
16.9%
(23.6, 51.7)
60.3%
(42.8, 75.1)
35%
(20.3, 51.3)
17.3%
(20.3, 51.3)
Etanercept 50 mg twice weekly64.8%
(46.7, 80.4)
39.4%
(23.2, 58.1)
19%
(23.2, 58.1)
63.3%
(40.8, 80.4)
38%
(19, 58.3)
19.5%
(19, 58.3)
Etanercept 50 mg and Methotrexate 20 mg once weekly63%
(44.4, 79.4)
37.5%
(21.5, 56.7)
17.7%
(21.5, 56.7)
61.6%
(38.7, 79.3)
36.2%
(17.5, 56.7)
18.2%
(17.5, 56.7)
Golimumab 50 mg58.4%
(43.3, 73.9)
33%
(20.6, 49.6)
14.7%
(20.6, 49.6)
55.9%
(35.3, 73.3)
30.9%
(15.3, 48.9)
14.6%
(15.3, 48.9)
Golimumab 100 mg57.2%
(42, 72.9)
32%
(19.7, 48.3)
14.1%
(19.7, 48.3)
55%
(34.6, 72.5)
30.1%
(14.8, 48)
14.1%
(14.8, 48)
Infliximab 5 mg/kg68.4%
(56.7, 79.9)
43.2%
(31.5, 57.5)
21.8%
(31.5, 57.5)
66.6%
(51.6, 79.3)
41.4%
(27.2, 56.8)
22%
(27.2, 56.8)
Infliximab 5 mg/kg and methotrexate 15 mg76.5%
(52, 92.1)
52.9%
(27.4, 77.7)
29.6%
(27.4, 77.7)
75.3%
(45, 92.2)
51.5%
(22, 77.9)
30.2%
(22, 77.9)
Abatacept 125 mg38.4%
(25.7, 51.6)
17.2%
(9.6, 27.1)
6%
(9.6, 27.1)
45.9%
(29.1, 63.8)
22.7%
(11.5, 38.4)
9.6%
(11.5, 38.4)
26.4%
(12.6, 45.1)
11.1%
(4.1, 23.9)
3.8%
(4.1, 23.9)
Placebo20.7%
(9.5, 37.3)
7.1%
(2.5, 16.5)
1.9%
(2.5, 16.5)
20.9%
(10.2, 36.4)†
7.2%
(2.7, 16)†
2.2%
(2.7, 16)†
18.3%
(9.6, 30.7)†
6.8%
(2.9, 13.8)†
2%
(2.9, 13.8)†
  • *Key comparators include bDMARDs at doses licensed for use in PsA or PsO.

  • †Based on a combination of studies reporting outcomes at week 12 or 16 and week 24.

  • ‡Based on studies reporting outcomes at week 24 only.

  • ACR, American College of Rheumatology; bDMARD, biological disease-modifying antirheumatic drug; PsA, psoriatic arthritis; PsO, psoriasis.